Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Apo-Si-K170A-C76 is an investigational pharmaceutical drug currently in phase 1 clinical development, administered via **intranasal spray**. Its primary purpose in clinical studies is to evaluate safety, tolerability, and systemic exposure in healthy adult subjects. The drug is delivered in ascending single and repeated twice-daily (BID) doses using a nasal spray device at a concentration of 20 mg/mL, with dosing varying by cohort. The developer and sponsor of the clinical trial is Interna Therapeutics Ltd. (formerly SirVir Ltd. / Aposense Ltd.), based in Israel. No details regarding the molecular structure, active pharmaceutical ingredient, or specific therapeutic indication beyond phase 1 safety evaluation in healthy volunteers are currently available from public sources[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Apo-Si-K170A-C76.